罗红霉素治疗冠心病的疗效观察  

Therapeutic effect of Roxithromycin in coronary artery disease

作　　者：王芬珍[1] 江挺[1] 吴炳元[1] 叶榕[1] 卓闽彬[1] 费正芳[1] 

机构地区：[1]福州市第一医院,福建福州350002

出　　处：《心血管康复医学杂志》2004年第6期542-544,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨罗红霉素在冠心病治疗中的作用。方法:选择符合冠心病诊断标准的60例血肺炎衣原体抗体IgG阳性患者,采用随机方法均分为罗红霉索治疗组及对照组,1个月后治疗组复查血肺炎衣原体抗体IgG,随访1年。结果:罗红霉素治疗组,3例出现心血管事件,发生率10％,对照组10例出现心血管事件,发生率33.3％,罗红霉素治疗组心血管事件发生率明显低于对照组(P<0.05),两组治疗前,治疗组治疗前、后肺炎衣原体抗体IgG滴度比较差异无显著性。结论:罗红霉素能减少冠心病心血管事件发生率。Objective: To explore the therapeutic effect of Roxithromycin in coronary artery disease (CAD). Methods: A total of 60 CAD patients with IgM antibody positive of chlamydia pneumoniae(Cp) were divided into Roxithromycin group (30 cases, treated with Roxithromycin 150 mg, bid) and control group (30 cases, no treated with Roxithromycin). IgM antibody of Cp was re-examined after therapy one month. The patients were followed up one year. Results: There were 3 cases (10%) occurred with events of cardiovascular in Roxithromycin group, but it were 10 cases (33%) in control group. Incidence of cardiovascular events of Roxithromycin group was less than control group (P<0. 05). Tilers of Cp were no significantly difference between two groups before and after therapy. Conclusion: Roxithromycin can decrease the incidence of cardiovascular events in CAD patients.

关 键 词：罗红霉素 治疗组 冠心病 心血管事件 发生率 肺炎衣原体抗体 对照组 治疗前 疗效观察 治疗中 

分 类 号：R541.4[医药卫生—心血管疾病] R554.6[医药卫生—内科学]